Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;9(4):513-26.
doi: 10.1177/1756283X16638833. Epub 2016 Apr 1.

Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease

Uri Kopylov  1 , Ernest Seidman  2
Affiliations
Review

Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease

Uri Kopylov et al. Therap Adv Gastroenterol. 2016 Jul.

Abstract

Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple clinical, genetic and immunopharmacological factors may impact the response to anti-TNFs. Early stratification of IBD patients by the expected risk of therapeutic failure during the induction and maintenance phases of treatment may allow for treatment optimization and potentially optimal short- and long-term outcomes. The aim of this review is to summarize the current data concerning the potential predictors of therapeutic success and failure of anti-TNFs in IBD.

Keywords: anti-TNF agents; inflammatory bowel disease; therapeutic drug monitoring.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

    1. Afif W., Loftus E., Jr., Faubion W., Kane S., Bruining D., Hanson K., et al. (2010) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. American Journal of Gastroenterology 105: 1133–1139. - PMC - PubMed
    1. Ainsworth M., Bendtzen K., Brynskov J. (2008) Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease. American Journal of Gastroenterology 103: 944–948. - PubMed
    1. Arias M., Vande Casteele N., Vermeire S., De Buck Van Overstraeten A., Billiet T., Baert F., et al. (2015) A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 13: 531–538. - PubMed
    1. Arnott I., Mcneill G., Satsangi J. (2003) An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharmacol Ther 17: 1451–1457. - PubMed
    1. Atreya R., Neumann H., Neufert C., Waldner M., Billmeier U., Zopf Y., et al. (2014) In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med 20: 313–318. - PMC - PubMed

LinkOut - more resources